Navigation Links
Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
Date:9/21/2007

ROCKVILLE, Md., Sept. 21 /PRNewswire/ -- Flexible Medical Systems (FMS) announced today that it has completed the private placement of $1.2 million of common equity to a group of accredited investors. The company will use the proceeds from the private placement to conduct human proof-of-concept trials, to pursue additional intellectual property filings and for general working capital.

"The proceeds from this investment will provide us with funding to pursue our business plan. We intend to demonstrate our proven animal study results in humans which will allow us to go to the next level," said Richard H. Smith, President. The company will occupy labs on Crabbs Branch Way in Rockville, MD.

FMS also announced that Paul A. Brown, M.D. has been elected to the company's board of directors. Dr. Brown, who holds an A.B. from Harvard College and an M.D. from Tufts University School of Medicine, is the founder and Chairman of HearUSA, Inc., a leading hearing care provider with more than 170 hearing care centers.

Before founding HearUSA in 1967, Dr. Brown was Chairman and CEO of MetPath, Inc., which offered a full range of clinical laboratory services to physicians and hospitals. Dr. Brown transformed MetPath into the largest clinical laboratory in the world with over 3,000 employees and secured its position on the American Stock Exchange. MetPath was sold to Corning in 1982 for $140 million. MetPath became Quest Diagnostics and today is the nation's leading provider of diagnostic testing, information and services with over $5 billion in annual revenues.

"Paul's extensive experience as a doctor, entrepreneur, and business leader within the challenging life science service business makes him an ideal member of FMS's board," said Founder and Chief Science Officer John F. Currie, Ph.D. "His integrity, strong leadership skills, and ability and willingness to confront and resolve tough issues will be extremely valuable to FMS as we continue to grow and
'/>"/>

SOURCE Flexible Medical Systems
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Gene Chips to Detect CYP Variations: A New Step Toward Customized Medical Therapy.
2. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
3. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
4. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
5. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
6. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
7. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
8. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
9. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
10. Inovio Biomedical Highlights Enhanced DNA Vaccine Potency with Electroporation DNA Delivery Technology and New Devices at Gene Therapy Meeting
11. World First Medical Treatment Announced by Researchers at Queen Mary University London and University of Leicester

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...inker.comannouncesthatanewmarketresearchreportisav...t-AGlobalMarketPerspective ,, http://www.rep...lobal-Market-Perspective.html ,, Risinginciden...nationsisaprincipalfactorinfluencinggrowthinthemam...eastcancerhasallowedwomentocomeforwardfortheiryear...
(Date:11/25/2009)...e/--SwissrayInternational,Inc.aleadingmanufacturer...todaythatitsoperationshavebeenacquiredbyaprivateSw...,smedicalimagingbrand.Theacquisitionincludedallass...entory.After25yearsofsuccessandgrowthSwissrayisnow...ntswithstableandsteadygrowth. ,, "Swissrayhaslo...
(Date:11/25/2009)...l/--NuVasive,Inc.(Nasdaq: NUVA ),amedicaldevicecom...ivesurgicaltreatmentsforthespine,announcedtodaytha...,at5:30p.m.ET/2:30p.m.PT.Theconferencecallwillfocu...ny,sproductsandwillincludecommentsfrommanagementfo...umbersare1-877-407-4018fordomesticcallersand1-201-...
Breaking Medicine Technology:Reportlinker Adds Mammography Equipment - A Global Market Perspective 2Reportlinker Adds Mammography Equipment - A Global Market Perspective 3Reportlinker Adds Mammography Equipment - A Global Market Perspective 4Reportlinker Adds Mammography Equipment - A Global Market Perspective 5Reportlinker Adds Mammography Equipment - A Global Market Perspective 6Reportlinker Adds Mammography Equipment - A Global Market Perspective 7Swissray International Announces New Ownership 2NuVasive Announces Conference Call and Webcast Regarding Reimbursement 2NuVasive Announces Conference Call and Webcast Regarding Reimbursement 3OPAXIO Produces High Rates of Pathologic Complete Remission in Patients with Advanced Esophageal Cancer 3B Study Paves Way for Potential Registration 5118 1OPAXIO Produces High Rates of Pathologic Complete Remission in Patients with Advanced Esophageal Cancer 3B Study Paves Way for Potential Registration 5118 2OPAXIO Produces High Rates of Pathologic Complete Remission in Patients with Advanced Esophageal Cancer 3B Study Paves Way for Potential Registration 5118 3OPAXIO Produces High Rates of Pathologic Complete Remission in Patients with Advanced Esophageal Cancer 3B Study Paves Way for Potential Registration 5118 4OPAXIO Produces High Rates of Pathologic Complete Remission in Patients with Advanced Esophageal Cancer 3B Study Paves Way for Potential Registration 5118 5LA BioMed study finds higher survival rate among intoxicated trauma patients 58613 1Algae and pollen grains provide evidence of remarkably warm period in Antarcticas history 10205 1Algae and pollen grains provide evidence of remarkably warm period in Antarcticas history 10205 2Algae and pollen grains provide evidence of remarkably warm period in Antarcticas history 10205 3Algae and pollen grains provide evidence of remarkably warm period in Antarcticas history 10205 4
...teria to Help Facilitate EHR Adoption in Small, Am..., March 3 The Certification Commission for Heal...rally recognized body for testing and certifying e...will develop dermatology-specific functionality cr... in part a response to an application from the Ame...
...IS, March 3 Novexel, a speciality pharmaceutical,...f novel antibiotics,designed to overcome the signi...unces today that its most advanced injectable anti... beta lactamase inhibitor, NXL104, with the,well e...has entered a second,Phase II clinical trial. , ...
Other Medicine Technology:Certification Commission for Healthcare Information Technology to Develop Dermatology-Specific Functionality Criteria for Electronic Health Record (EHR) Technology 2Novexel's NXL104/ceftazidime Combination Commences Second Phase II Clinical Trial in Hospital Patients With Complicated Intra-Abdominal Infections (cIAIs) 2Novexel's NXL104/ceftazidime Combination Commences Second Phase II Clinical Trial in Hospital Patients With Complicated Intra-Abdominal Infections (cIAIs) 3Novexel's NXL104/ceftazidime Combination Commences Second Phase II Clinical Trial in Hospital Patients With Complicated Intra-Abdominal Infections (cIAIs) 4
(Date:11/26/2009)... No more letters from the North Po...lized text messages from Santa , ...increase operational efficiencies at the North Pol... keep children all over the globe informed of his ... Santa’s research department have identified...
(Date:11/25/2009)...DINA,Minn.,Nov.25/PRNewswire-USNewswire/--Whenmost...tachiropractorcanalsogivepatientsthehelptheyneed.T...eyourjaw(mandible)contacts/connectswithyourskull(t...dwithTMJdysfunctionarepainwithchewing,clickingorpo...MJdysfunctionincluding:headaches,fatigue,sleepdist...
(Date:11/25/2009)...ONGBEACH,Calif.,Nov.25/PRNewswire/--Thanksgivingme...iorsinthegreaterLongBeachareathankstoFaithInAction...denceatHome(IAH),adivisionofSCANHealthPlan.Formore...fvolunteerstodeliverwarmThanksgivingmealstoseniors...thLosAngelesandsurroundingcities. ,, "Ourwarmho...
(Date:11/25/2009)...rm survivors of testicular cancer who were treated... side effects, including neurological side effects... treated with chemotherapy, according to a new stu... the National Cancer Institute . , Marianne Bryd...University Hospital, in Bergen, Norway, and collea...
(Date:11/25/2009)..., already used to fight rheumatoid arthritis, coul... , WEDNESDAY, Nov. 25 (HealthDay News) -- A...a and rheumatoid arthritis now also shows some pro... 1 diabetes. , The drug, rituximab (Rituxan), h...sulin, even though the disease had destroyed some ...
Breaking Medicine News(10 mins):Health News:Text Messages from Santa | Santa goes GREEN by going MOBILE for The March of Dimes 2Health News:SCAN Employees and Community Volunteers to Help Deliver One Thousand Thanksgiving Meals to Homebound Seniors 2Health News:Type 1 Diabetes May Have a New Foe 2Health News:Type 1 Diabetes May Have a New Foe 3
...egory Laslo will travel to Washington, D.C., Sunda...t with congressional leaders and gain their suppor...earch toward a cure for epilepsy. , , Rundlett, 1...th support from Abbott. The program rallies young ...
... Phoenix, AZ, will travel to Washington, D.C., Su...meet with congressional leaders and gain their sup...research toward a cure for epilepsy. , , McArthur...nd funded by Abbott Laboratories. The program rall...
...use from intimate partners spent 42 percent more o...rding to a long-term study of more than 3,000 wome... The study revealed that women who suffered physic...cal and emotional pain it causes, domestic violenc...
...ces, Inc. announced today that it has provided $19...spital in Mountain View, California. The five-year...y of Siemens Medical Solutions equipment which wil...e than 40 years, El Camino Hospital has been servi...
...ty, IA will travel to Washington, D.C., Sunday, Ma...h congressional leaders and gain their support for... toward a cure for epilepsy. , , Carlson, 16, is ... by Abbott Laboratories. The program rallies young...
...Inc., the premier cancer diagnostics company and t...ay announced the appointment of Grady Barnes, Ph.D...o Fujirebio Diagnostics with 25 years of diagnosti...dian Bioscience. , , As Chief Scientific Officer,...
Other Medicine News:Health News:Maryland Youths Share Epilepsy Message on Capitol Hill 2Health News:Arizona Youth Shares Epilepsy Message on Capitol Hill 2Health News:Physical abuse raises women's health costs over 40 percent 2Health News:Siemens Financial Services, Inc. Announces Completion of Tax-Exempt Financing With El Camino Hospital 2Health News:Siemens Financial Services, Inc. Announces Completion of Tax-Exempt Financing With El Camino Hospital 3Health News:Iowa Youth Shares Epilepsy Message on Capitol Hill 2Health News:Fujirebio Diagnostics Appoints Grady Barnes as Chief Scientific Officer 2
USA Series MICRO-6L Semi-Rigid Ureteroscope
...he ACMI DUR-8 Elite's 8.7 Fr shaft reaches into th...iding complete intrarenal access, even reaching th... covering and working channel ease insertion of bo...stable shaft construction, tight-bend radius tip, ...
...he ACMI USA Series DUR-8 Durable Flexible Ureteros...e entire intrarenal collecting system with little ... secondary deflection allow complete intrarenal ac...ction facilitates access to the proximal ureter an...
S-Series Cystourethroscope Standard Obturator
Medicine Products: